Glenmark Pharmaceuticals shares rise 3% after DCGI approval for Envafolimab trial in non-small cell lung cancer patients.

Glenmark Pharmaceuticals shares rose 3.05% to ₹2,051.40 after receiving DCGI approval to start a Phase 3 trial of Envafolimab, a PD-L1 inhibitor, for resectable Stage III non-small cell lung cancer. The trial will evaluate the drug's efficacy, safety, and pharmacokinetics in patients across multiple countries, including India, Russia, Brazil, and Mexico. Envafolimab has the potential to make immunotherapy more accessible and convenient for patients worldwide.